Biogen To Submit Spinraza To UK's NICE For SMA, While Australia Wants More Data
Executive Summary
Biogen’s Spinraza for the rare disease spinal muscular atrophy is to be assessed by NICE, the UK HTA body for England and Wales. In the interim it will be made available under a managed access deal. The product is also being assessed by Australia’s PBAC, which has asked for more cost-effectiveness data and may require a reduction in the company’s proposed price.
You may also be interested in...
Scotland To Improve Early Patient Access to ‘Ultra-Orphan’ Drugs
Scotland is changing that way that medicines for very rare diseases are assessed by the health technology assessment body, the SMC. The changes include a new definition of “ultra-orphan medicine” and a new system for provisionally funding such products while more evidence is gathered on their effectiveness
Biogen’s Spinraza Needs Long-Term Confirmatory Data, Says EMA
The EMA may have quickly assessed the US biotech’s antisense spinal muscular atrophy therapy for Europe, but the product’s rapid clinical development means long-term data, and data on its effects in milder disease, or even cures, still need to be collected.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.